List of chemotherapy regimens: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (→‎Overview: regimen add)
 
(21 intermediate revisions by 4 users not shown)
Line 1: Line 1:
{{SI}}
__NOTOC__
 
{{Seealso|List of chemotherapeutic agents}}
'''Associate Editor-in-Chief:''' Ross Bonander
{{CMG}}; {{AE}} {{AV}}
 
{{EJ}}


==Overview==
==Overview==
Acronyms often identify the individual agents used in combination '''chemotherapy regimens'''. Unfortunately, the letters used are not consistent across regimens, and in some cases (for example, "BEACOPP") the same letter is used to represent two different treatments. Because of this, there is not a naming standard for chemotherapy regimens, and this page merely represents commonly used conventions.
A '''chemotherapy regimen''' is a regimen for [[chemotherapy]] defining the drugs to be used, their dosage, the frequency and duration of treatments and other considerations.  In modern [[oncology]] almost all regimens in use combine several [[list of chemotherapeutic agents|chemotherapy drugs]] in combination chemotherapy.  Acronyms often identify the individual agents used in combination chemotherapy regimens. Unfortunately, the letters used are not consistent across regimens, and in some cases (for example, "BEACOPP") the same letter is used to represent two different treatments. Because of this, there is not a naming standard for chemotherapy regimens, and this page merely represents commonly used conventions.
 
The term "Induction regimens" refers to a chemotherapy regimen which is used for the initial treatment of a disease.
 
{| class="wikitable"
! Name !! Components !! Example of uses, and other notes


==List of Chemotherapy Regimens==
{| style="font-weight: bold;"
! style="font-size: 85%; background: #545454; color: #F8F8FF;" | Regimen
! style="font-size: 85%; background: #545454; color: #F8F8FF;" | Indications
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[7+3 regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Acute myelogenous leukemia
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[ABVD regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Hodgkin's lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[ABVE-PC regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Hodgkin's lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[AC regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Breast cancer
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[ACVBP-R regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Diffuse large B-cell lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[ADOC regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Thymoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[BACOD regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Diffuse large B-cell lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[BEACOPP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Hodgkin's lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[BEP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Ovarian and testicular germ-cell tumors
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[CA regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Breast cancer
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[CAF regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Breast cancer
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[CAPOX regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Colorectal cancer
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[CAV regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Small cell lung cancer
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[CBV regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Acute leukemia
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[CDOP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Diffuse large B-cell lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[CEOP-R regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Diffuse large B-cell lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[CEPP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Hodgkin's lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[ChlVPP-EVA regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Hodgkin's lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[CHOEP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Diffuse large B-cell lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[CHOP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[CHOP-R regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Diffuse large B-cell lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[ClaPD regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Multiple Myeloma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[CMF regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Breast cancer
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[CMV regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Bladder carcinoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[CNOP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[CODOX-M/IVAC regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Burkitt's lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[COP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[COPP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Hodgkin's lymphoma, Non-Hodgkin's lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[CT regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Ovarian cancer
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[CTD regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Multiple Myeloma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[CVAD regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Multiple Myeloma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[CVP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[CyBorD regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Multiple Myeloma, AL amyloidosis
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[DA-EPOCH regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[DA-R-EPOCH regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[DBVE-PC regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Hodgkin's lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[DCEP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Multiple Myeloma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[DHAP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Hodgkin's lymphoma, Non-Hodgkin's lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[DHAX-R regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[DICE regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[DT-PACE regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Multiple Myeloma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[EC regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Small cell lung cancer
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[ECF regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Gastric cancer
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[EOX regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Oesophageal cancer
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[EP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Small cell lung cancer
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[EPOCH regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[EPOCH-R regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[ESHAP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Hodgkin's lymphoma, Non-Hodgkin's lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[ESHAP-R regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Hodgkin's lymphoma, Non-Hodgkin's lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[FAM regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Gastric cancer, Pancreatic cancer
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[FCM regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma, Mantle cell lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[FCM-R regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Chronic lymphocytic leukemia
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[FEC regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Breast cancer
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[FL regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Colon cancer
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[FLAG regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Acute myeloid leukemia
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[FLAG-Ida regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Myelodysplastic syndromes and Acute myeloid leukaemia
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[FLAG-Mito regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Acute myelogenous leukemia
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[FLAMSA regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Myelodysplastic syndrome, acute myelogenous leukemia secondary to MDS
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[FLAMSA-BU regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Myelodysplastic syndrome, acute myelogenous leukemia secondary to MDS
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[FLAMSA-MEL regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Myelodysplastic syndrome, acute myelogenous leukemia secondary to MDS
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[FM regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-hodgkin lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[FMC regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Chronic lymphocytic leukaemia
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[FMC-R regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin lymphoma, mantle cell lymphoma, CLL
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[FMR regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-hodgkin lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[FN-D regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[FOLFIRI regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Colorectal cancer
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[FOLFIRINOX regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Pancreatic cancer
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[FOLFOX regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Colorectal cancer
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[GemOx regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Biliary adenocarcinoma, Pancreatic cancer, Hepatocellular cancer, Testicular cancer
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[GemOx-R regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[GVD regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Hodgkins lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[HYPER-CVAD regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Multiple myeloma, diffuse large B-cell lymphoma, Burkitt's lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[IA regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Acute myelogenous leukemia
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[IAC regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Acute myelogenous leukemia
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[ICE regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma, Hodgkin's lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[ICE-R regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[Ida-FLAG regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Myelodysplastic syndromes and Acute myeloid leukaemia
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[IFL regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Colorectal cancer
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[LR-CHOP-21 regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[m-BACOD regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[MACOP-B regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[MCOP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma
|-
|-
| '''[[ABVD]]''' <ref name="pmid54209">{{cite journal |author=Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C |title=Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP |journal=Cancer |volume=36 |issue=1 |pages=252–9 |year=1975 |month=July |pmid=54209 |doi= |url=}}</ref>
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[MINE regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma, Hodgkin's lymphoma
| [[Adriamycin]], [[bleomycin]], [[vinblastine]], [[dacarbazine]]
| [[Hodgkin's lymphoma]]
|-
|-
|'''ABVE-PC''' <ref name="pmid19584400">{{cite journal |author=Schwartz CL, Constine LS, Villaluna D, ''et al.'' |title=A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425 |journal=Blood |volume=114 |issue=10 |pages=2051–9 |year=2009 |month=September |pmid=19584400 |doi=10.1182/blood-2008-10-184143 |url=}}</ref>
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[MINE-R regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma, Hodgkin's lymphoma
| Doxorubicin, bleomycin, vincristine, etoposide, prednisone, cyclophosphamide
| Pediatric Hodgkin's lymphoma
|-
|-
| '''AC'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[Mini-BEAM regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Hodgkin's lymphoma
| [[Adriamycin]]/[[Doxorubicin]], [[Cyclophosphamide]]
| [[Breast cancer]]
|-
|-
| '''[[ADOC]]''' <ref name="pmid10555755">{{cite journal |author=Berruti A, Borasio P, Gerbino A, ''et al.'' |title=Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience |journal=Br. J. Cancer |volume=81 |issue=5 |pages=841–5 |year=1999 |month=November |pmid=10555755 |pmc=2374302 |doi=10.1038/sj.bjc.6690773 |url=}}</ref>
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[Mito-FLAG regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Acute myelogenous leukemia
| [[Doxorubicin]], [[cisplatin]], [[vincristine]], [[cyclophosphamide]]
| [[Thymic carcinoma]]
|-
|-
| '''[[BEACOPP]]''' <ref name="pmid9850026">{{cite journal |author=Diehl V, Franklin J, Hasenclever D, ''et al.'' |title=BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group |journal=J. Clin. Oncol. |volume=16 |issue=12 |pages=3810–21 |year=1998 |month=December |pmid=9850026 |doi= |url=}}</ref>
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[MOPP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Hodgkin's lymphoma
| [[Bleomycin]], [[etoposide]], [[Adriamycin]] ([[doxorubicin]]), [[cyclophosphamide]], [[Oncovin]] ([[vincristine]]), [[procarbazine]], [[prednisone]]
| [[Hodgkin's lymphoma]]
|-
|-
| '''[[BEP]]'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[MVAC regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Bladder cancer
| [[Bleomycin]], [[etoposide]], platinum ([[cisplatin]])
| [[Testicular cancer]], [[germ cell tumor]]s
|-
|-
| '''CAF'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[PCV regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Oligodendroglial tumors
| [[Cyclophosphamide]], [[Adriamycin]]/[[Doxorubicin]], [[5-FU]]/[[Fluorouracil]]
| [[Breast cancer]]
|-
|-
| '''CAV'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[POG 9245 regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Hodgkin's lymphoma
| [[Cyclophosphamide]], [[Adriamycin]]/[[Doxorubicin]], [[Vincristine]]
| [[Lung cancer]]
|-
|-
| '''[[CHOP]]'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[ProMACE-CytaBOM regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma
| [[Cyclophosphamide]], [[doxorubicin]] ([[hydroxydoxorubicin]]), vincristine ([[Oncovin]]), [[prednisone]]
| [[Non-Hodgkin lymphoma]]
|-
|-
| '''[[CHOP-R]]'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[ProMACE-MOPP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Diffuse large B-cell lymphoma, primary CNS lymphoma
| CHOP + [[rituximab]]
| [[B cell]] [[non-Hodgkin lymphoma]]
|-
|-
| '''[[CHOP|COP]]''' or '''[[CHOP|CVP]]'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[R-CDOP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma
| [[Cyclophosphamide]], [[vincristine]] (Oncovin), and [[prednisone]]
| Non-Hodgkin lymphoma in patients with history of [[cardiovascular disease]]
|-
|-
| '''[[CMF (therapy)|CMF]]'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[R-CEOP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Diffuse large B-cell lymphoma
| [[Cyclophosphamide]], [[Methotrexate]], and [[5-Fluorouracil]]
| [[Breast Cancer]]
|-
|-
| '''CODOC-M/IVAC''' <ref name="pmid12181251">{{cite journal |author=Mead GM, Sydes MR, Walewski J, ''et al.'' |title=An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study |journal=Ann. Oncol. |volume=13 |issue=8 |pages=1264–74 |year=2002 |month=August |pmid=12181251 |doi= |url=}}</ref>
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[R-CHMP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma
| Cyclophosphamide, vincristine, doxorubicin, methotrexate (CODOX-M) + ifosfamide, etopiside (VP-16), cytarabine (Ara-C) (IVAC)
| [[Burkitt's lymphoma]]
|-
|-
| '''[[COPP]]'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[R-CHOEP-14 regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Diffuse large B-cell lymphoma
| [[Cyclophosphamide]], Oncovin (vincristine), [[procarbazine]] and prednisone
| [[Non-Hodgkin lymphoma]]
|-
|-
| '''DA-EPOCH''' <ref name="pmid11929754">{{cite journal |author=Wilson WH, Grossbard ML, Pittaluga S, ''et al.'' |title=Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy |journal=Blood |volume=99 |issue=8 |pages=2685–93 |year=2002 |month=April |pmid=11929754 |doi= |url=}}</ref>
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[R-CHOP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Diffuse large B-cell lymphoma
| Dose-adjusted [[Etopiside]], [[prednisone]], [[vincristine]] (Oncovin), [[Cyclophosphamide]] and doxorubicin
| Newly diagnosed, aggressive [[non-Hodgkin lymphoma]]
|-
|-
| '''DHAP''' <ref name="pmid3334893">{{cite journal |author=Velasquez WS, Cabanillas F, Salvador P, ''et al.'' |title=Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP) |journal=Blood |volume=71 |issue=1 |pages=117–22 |year=1988 |month=January |pmid=3334893 |doi= |url=}}</ref>
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[R-CVP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Diffuse large B-cell lymphoma
| Dexamethasone, cytarabine (high-dose ARA-C), cisplatin
| Recurrent or refractory [[non-Hodgkin lymphoma]]
|-
|-
| '''EC'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[R-DHAOx regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Follicular lymphoma
| [[Epirubicin]], [[Cyclophosphamide]]
| [[Breast cancer]]
|-
|-
| '''ECF'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[R-EPOCH regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Hodgkin's lymphoma, HIV-associated lymphoma
| [[Epirubicin]], [[cisplatin]], [[fluorouracil]]
| [[Gastric cancer]] and [[oesophageal cancer]]
|-
|-
| '''ESHAP'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[R-ESHAP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Diffuse large B-cell lymphoma
| [[Etopiside]], methylprednisolone (Solu-medrol), cytarabine (ARA-C), cisplatin
| Relapsed or refractory [[non-Hodgkin lymphoma]]
|-
|-
| '''FN-D''' <ref name="pmid8648382">{{cite journal |author=McLaughlin P, Hagemeister FB, Romaguera JE, ''et al.'' |title=Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma |journal=J. Clin. Oncol. |volume=14 |issue=4 |pages=1262–8 |year=1996 |month=April |pmid=8648382 |doi= |url=}}</ref>
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[R-FCM regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Chronic lymphocytic leukemia
| Fludarabine, mitoxantrone (Novantrone), dexamethasone
| Recurrent or refractory indolent [[non-Hodgkin lymphoma]]
|-
|-
| '''FOLFIRI''' <ref name="pmid10744089">{{cite journal |author=Douillard JY, Cunningham D, Roth AD, ''et al.'' |title=Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial |journal=Lancet |volume=355 |issue=9209 |pages=1041–7 |year=2000 |month=March |pmid=10744089 |doi= |url=}}</ref>
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[R-FMC regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Chronic lymphocytic leukemia
| Leucovorin, infusional fluorouracil, irinotecan
| Metastatic [[colorectal cancer]]
|-
|-
| '''[[FOLFOX]]'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[R-GCVP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Diffuse large B-cell lymphoma
| [[Fluorouracil]], [[leucovorin]] ([[folinic acid]]), and [[oxaliplatin]]
| [[Colorectal cancer]]
|-
|-
| '''HYPER-CVAD''' <ref name="pmid10561310">{{cite journal |author=Thomas DA, Cortes J, O'Brien S, ''et al.'' |title=Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia |journal=J. Clin. Oncol. |volume=17 |issue=8 |pages=2461–70 |year=1999 |month=August |pmid=10561310 |doi= |url=}}</ref>
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[R-HCVAD regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Mantle cell lymphoma
| Hyperfractionated cyclophosphamide, vincristine (Oncovin), doxorubicin (Adriamycin), dexamethasone ([[Decadron]])
| [[Burkitt's lymphoma]]
|-
|-
| '''ICE''' <ref name="pmid10577849">{{cite journal |author=Moskowitz CH, Bertino JR, Glassman JR, ''et al.'' |title=Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma |journal=J. Clin. Oncol. |volume=17 |issue=12 |pages=3776–85 |year=1999 |month=December |pmid=10577849 |doi= |url=}}</ref>'
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[R-MA regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Mantle cell lymphoma
| Ifosfamide, carboplatin, etopiside
| Relapsed or primary refractory [[non-Hodgkin lymphoma]]
|-
|-
| '''ICE-R'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[R-MINE regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Hodgkin's lymphoma, non-Hodgkin's lymphoma
| ICE + [[rituximab]]  
| Relapsed or primary refractory [[non-Hodgkin lymphoma]]
|-
|-
| '''IFL''' <ref name="pmid11006366">{{cite journal |author=Saltz LB, Cox JV, Blanke C, ''et al.'' |title=Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group |journal=N. Engl. J. Med. |volume=343 |issue=13 |pages=905–14 |year=2000 |month=September |pmid=11006366 |doi= |url=}}</ref>
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[R2CHOP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Diffuse large B-cell lymphoma
| [[Irinotecan]], [[bolus fluorouracil]] and leucovorin
| Metastatic [[Colorectal cancer|colorectal cancer]]
|-
|-
| '''m-BACOD'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[RCD regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-hodgkin lymphoma, CLL
| [[Methotrexate]], [[bleomycin]], doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), dexamethasone ([[Decadron]])
| [[Non-Hodgkin lymphoma]]
|-
|-
| '''MACOP-B''' <ref name="pmid2580468">{{cite journal |author=Klimo P, Connors JM |title=MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma |journal=Ann. Intern. Med. |volume=102 |issue=5 |pages=596–602 |year=1985 |month=May |pmid=2580468 |doi= |url=}}</ref>
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[RdC regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | AL amyloidosis
| [[Methotrexate]], [[leucovorin]], [[doxorubicin]] (Adriamycin), [[cyclophosphamide]], [[vincristine]] (Oncovin), [[prednisone]], [[bleomycin]]
| Non-Hodgkin lymphoma
|-
|-
| '''Mini-BEAM''' <ref name="pmid7844600">{{cite journal |author=Colwill R, Crump M, Couture F, ''et al.'' |title=Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation |journal=J. Clin. Oncol. |volume=13 |issue=2 |pages=396–402 |year=1995 |month=February |pmid=7844600 |doi= |url=}}</ref>
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[RVD regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Multiple myeloma
| Carmustine (BCNU), etopiside, cytarabine (Ara-C), melphalan
| Hodgkin's lymphoma ([[Salvage therapy]], pre-[[Stem cell transplantation|transplant]])
|-
|-
| '''[[MOPP (medicine)|MOPP]]'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[SMILE regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | NK/T cell lymphoma
| [[Mechlorethamine]], [[vincristine]] ([[oncovin]]), [[procarbazine]], [[prednisone]]
| [[Hodgkin's lymphoma]]
|-
|-
| '''MVAC''' <ref name="pmid11001674">{{cite journal |author=von der Maase H, Hansen SW, Roberts JT, ''et al.'' |title=Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study |journal=J. Clin. Oncol. |volume=18 |issue=17 |pages=3068–77 |year=2000 |month=September  pmid=11001674 |doi= |url=}}</ref>
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[Stanford V regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Hodgkin's lymphoma
| Methotrexate, vinblastine, doxorubicin, cisplatin
| [[Bladder cancer]]
|-
| '''NABTT''' <ref name="pmid11835382">{{cite journal |author=Herrlinger U, Schabet M, Brugger W, ''et al.'' |title=German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma |journal=Ann. Neurol. |volume=51 |issue=2 |pages=247–52 |year=2002 |month=February |pmid=11835382 |doi= |url=}}</ref>
| Methotrexate, calcium leucovorin; methotrexate, calcium leucovorin; methotrexate, calcium leucovorin
| [[Primary central nervous system lymphoma|Primary CNS lymphoma]]
|-
|-
| '''[[PCV]]''' <ref name="pmid7407756">{{cite journal |author=Levin VA, Edwards MS, Wright DC, ''et al.'' |title=Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors |journal=Cancer Treat Rep |volume=64 |issue=2-3 |pages=237–44 |year=1980 |pmid=7407756 |doi= |url=}}</ref>
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[TAC regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Breast cancer
| [[Procarbazine]], [[lomustine]] (CCNU), [[vincristine]]
| [[Brain tumors]]
|-
|-
| '''ProMACE-MOPP'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[TAP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Endometrial cancer
| [[Methotrexate]], [[doxorubicin]] (Adriamycin), [[cyclophosphamide]], [[etoposide]] + [[MOPP (medicine)|MOPP]]
| Non-Hodgkin lymphoma
|-
|-
| '''ProMACE-CytaBOM'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[TC regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Breast cancer
| [[Prednisone]], [[doxorubicin]] ([[adriamycin]]), [[cyclophosphamide]], [[etoposide]], [[cytarabine]], [[bleomycin]], [[vincristine ]](Oncovin), [[methotrexate]], [[leucovorin]]
| [[Non-Hodgkin lymphoma]]
|-
|-
| '''R-FCM'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[TCH regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Breast cancer
| [[Rituximab]], [[fludarabine]], [[cyclophosphamide]], [[mitoxantrone]]
| [[B cell]] non-Hodgkin lymphoma
|-
|-
| '''RTOG 93-10''' <ref name="pmid12488408">{{cite journal |author=DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ |title=Combination chemotherapy and radiotherapy for primary central nervous system
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[Thal/Dex regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Multiple myeloma
| lymphoma: Radiation Therapy Oncology Group Study 93-10 |journal=J. Clin. Oncol. |volume=20 |issue=24 |pages=4643–8 |year=2002 |month=December |pmid=12488408 |doi= |url=}}</ref>
| Methotrexate, Leucovorin, vincristine, procarbazine, methotrexate, Leucovorin
| [[Primary central nervous system lymphoma|Primary CNS lymphoma]]
|-
|-
| '''[[Stanford V]]''' <ref name="pmid7537796">{{cite journal |author=Bartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ |title=Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report |journal=J. Clin. Oncol. |volume=13 |issue=5 |pages=1080–8 |year=1995 |month=May |pmid=7537796 |doi= |url=}}</ref>
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[TIP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Head and neck cancer, Testicular cancer
| [[Doxorubicin]] ([[Adriamycin]]), [[mechlorethamine]], [[bleomycin]], vinblastine, vincristine (Oncovin), etoposide ([[VP-16]]), prednisone
| Hodgkin's lymphoma
|-
|-
| '''TAC''' <ref name="pmid11208821">{{cite journal |author=Nabholtz JM, Mackey JR, Smylie M, ''et al.'' |title=Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer |journal=J. Clin. Oncol. |volume=19 |issue=2 |pages=314–21 |year=2001 |month=January |pmid=11208821 |doi= |url=}}</ref>
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[VAC regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Small cell lung cancer
| Docetaxel, doxorubicin, cyclophosphamide
| Metastatic breast cancer
|-
|-
| '''TAP''' <ref name="pmid15169803">{{cite journal |author=Fleming GF, Brunetto VL, Cella D, ''et al.'' |title=Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study |journal=J. Clin. Oncol. |volume=22 |issue=11 |pages=2159–66 |year=2004 |month=June |pmid=15169803 |doi=10.1200/JCO.2004.07.184 |url=}}</ref>
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[VAD regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Multiple myeloma
| Paclitaxel, doxorubicin, cisplatin
| [[Endometrial cancer]]
|-
|-
| '''Thal/Dex'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[VAPEC-B regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin lymphoma
| [[Thalidomide]], dexamethasone
| Multiple myeloma
|-
|-
| '''Treanda + Rituxan'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[VCAP-AMP-VECP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Human T-lymphotropic virus type I-associated Adult T-cell leukemia-lymphoma
| [[Bendamustine]], [[Rituximab]]
| Indolent and [[mantle cell lymphoma|mantle cell lymphomas]]
|-
|-
| '''[[VAD]]'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[VeIP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Germ cell tumor
| [[Vincristine]], [[Adriamycin]] (doxorubicin), [[dexamethasone]]
| [[Multiple myeloma]]
|-
|-
| '''VCAP-AMP-VECP''' <ref name="pmid17968021">{{cite journal |author=Tsukasaki K, Utsunomiya A, Fukuda H, ''et al.'' |title=VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801 |journal=J. Clin. Oncol. |volume=25 |issue=34 |pages=5458–64 |year=2007 |month=December |pmid=17968021 |doi=10.1200/JCO.2007.11.9958 |url=}}</ref>
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[VIP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Germ cell tumor, Thymoma
| Vincristine, cyclophosphamide, doxorubicin, and prednisone (VCAP)--doxorubicin, [[ranimustine]], and prednisone (AMP)-- [[vindesine]], etoposide, carboplatin, and prednisone (VECP)
| Adult T-cell leukemia-lymphoma (ATLL)
|-
|-
| '''VeIP''' <ref name="pmid9667270">{{cite journal |author=Loehrer PJ, Gonin R, Nichols CR, Weathers T, Einhorn LH |title=Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor |journal=J. Clin. Oncol. |volume=16 |issue=7 |pages=2500–4 |year=1998 |month=July |pmid=9667270 |doi= |url=}}</ref>
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[VR-CHOP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Diffuse large B-cell lymphoma and Mantle cell lymphoma
| Vinblastine, ifosfamide, cisplatin
| [[Testicular cancer]]
|-
|-
| '''VIP''' <ref name="pmid9552027">{{cite journal |author=Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ |title=Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study |journal=J. Clin. Oncol. |volume=16 |issue=4 |pages=1287–93 |year=1998 |month=April |pmid=9552027 |doi= |url=}}</ref>
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[VTD-PACE regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Multiple myeloma
| Etopiside, ifosfamide, cisplatin
| [[Testicular cancer]]
 
|}
|}


{{Reflist}}
==External Links==
 
* [http://www.cancer.gov/drugdictionary/ NCI Drug Dictionary]
==See also==
* [http://ncit.nci.nih.gov/ncitbrowser/pages/home.jsf NCI Thesaurus]
* [[Chemotherapy]]
* [http://hemonc.org/wiki/Drug_index HemOnc.org Drug Index]
* [[Salvage therapy|Salvage chemotherapy]]
* [[National Comprehensive Cancer Network|Treatment Guidelines]]
* [[National Comprehensive Cancer Network]]
 
==External links==
* [http://www.christie.nhs.uk/patients/booklets/chemo_index.aspx Christie Hospital Patient Information]
 
[[Category:Chemotherapeutic agents]]


{{Chemotherapeutic Agents}}
[[Category:Chemotherapy regimens| ]]
{{SIB}}
{{WikiDoc Help Menu}}
{{WS}}

Latest revision as of 20:19, 4 April 2015

Template:Seealso Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]

Overview

A chemotherapy regimen is a regimen for chemotherapy defining the drugs to be used, their dosage, the frequency and duration of treatments and other considerations. In modern oncology almost all regimens in use combine several chemotherapy drugs in combination chemotherapy. Acronyms often identify the individual agents used in combination chemotherapy regimens. Unfortunately, the letters used are not consistent across regimens, and in some cases (for example, "BEACOPP") the same letter is used to represent two different treatments. Because of this, there is not a naming standard for chemotherapy regimens, and this page merely represents commonly used conventions.

List of Chemotherapy Regimens

Regimen Indications
7+3 regimen Acute myelogenous leukemia
ABVD regimen Hodgkin's lymphoma
ABVE-PC regimen Hodgkin's lymphoma
AC regimen Breast cancer
ACVBP-R regimen Diffuse large B-cell lymphoma
ADOC regimen Thymoma
BACOD regimen Diffuse large B-cell lymphoma
BEACOPP regimen Hodgkin's lymphoma
BEP regimen Ovarian and testicular germ-cell tumors
CA regimen Breast cancer
CAF regimen Breast cancer
CAPOX regimen Colorectal cancer
CAV regimen Small cell lung cancer
CBV regimen Acute leukemia
CDOP regimen Diffuse large B-cell lymphoma
CEOP-R regimen Diffuse large B-cell lymphoma
CEPP regimen Hodgkin's lymphoma
ChlVPP-EVA regimen Hodgkin's lymphoma
CHOEP regimen Diffuse large B-cell lymphoma
CHOP regimen Non-Hodgkin's lymphoma
CHOP-R regimen Diffuse large B-cell lymphoma
ClaPD regimen Multiple Myeloma
CMF regimen Breast cancer
CMV regimen Bladder carcinoma
CNOP regimen Non-Hodgkin's lymphoma
CODOX-M/IVAC regimen Burkitt's lymphoma
COP regimen Non-Hodgkin's lymphoma
COPP regimen Hodgkin's lymphoma, Non-Hodgkin's lymphoma
CT regimen Ovarian cancer
CTD regimen Multiple Myeloma
CVAD regimen Multiple Myeloma
CVP regimen Non-Hodgkin's lymphoma
CyBorD regimen Multiple Myeloma, AL amyloidosis
DA-EPOCH regimen Non-Hodgkin's lymphoma
DA-R-EPOCH regimen Non-Hodgkin's lymphoma
DBVE-PC regimen Hodgkin's lymphoma
DCEP regimen Multiple Myeloma
DHAP regimen Hodgkin's lymphoma, Non-Hodgkin's lymphoma
DHAX-R regimen Non-Hodgkin's lymphoma
DICE regimen Non-Hodgkin's lymphoma
DT-PACE regimen Multiple Myeloma
EC regimen Small cell lung cancer
ECF regimen Gastric cancer
EOX regimen Oesophageal cancer
EP regimen Small cell lung cancer
EPOCH regimen Non-Hodgkin's lymphoma
EPOCH-R regimen Non-Hodgkin's lymphoma
ESHAP regimen Hodgkin's lymphoma, Non-Hodgkin's lymphoma
ESHAP-R regimen Hodgkin's lymphoma, Non-Hodgkin's lymphoma
FAM regimen Gastric cancer, Pancreatic cancer
FCM regimen Non-Hodgkin's lymphoma, Mantle cell lymphoma
FCM-R regimen Chronic lymphocytic leukemia
FEC regimen Breast cancer
FL regimen Colon cancer
FLAG regimen Acute myeloid leukemia
FLAG-Ida regimen Myelodysplastic syndromes and Acute myeloid leukaemia
FLAG-Mito regimen Acute myelogenous leukemia
FLAMSA regimen Myelodysplastic syndrome, acute myelogenous leukemia secondary to MDS
FLAMSA-BU regimen Myelodysplastic syndrome, acute myelogenous leukemia secondary to MDS
FLAMSA-MEL regimen Myelodysplastic syndrome, acute myelogenous leukemia secondary to MDS
FM regimen Non-hodgkin lymphoma
FMC regimen Chronic lymphocytic leukaemia
FMC-R regimen Non-Hodgkin lymphoma, mantle cell lymphoma, CLL
FMR regimen Non-hodgkin lymphoma
FN-D regimen Non-Hodgkin's lymphoma
FOLFIRI regimen Colorectal cancer
FOLFIRINOX regimen Pancreatic cancer
FOLFOX regimen Colorectal cancer
GemOx regimen Biliary adenocarcinoma, Pancreatic cancer, Hepatocellular cancer, Testicular cancer
GemOx-R regimen Non-Hodgkin's lymphoma
GVD regimen Hodgkins lymphoma
HYPER-CVAD regimen Multiple myeloma, diffuse large B-cell lymphoma, Burkitt's lymphoma
IA regimen Acute myelogenous leukemia
IAC regimen Acute myelogenous leukemia
ICE regimen Non-Hodgkin's lymphoma, Hodgkin's lymphoma
ICE-R regimen Non-Hodgkin's lymphoma
Ida-FLAG regimen Myelodysplastic syndromes and Acute myeloid leukaemia
IFL regimen Colorectal cancer
LR-CHOP-21 regimen Non-Hodgkin's lymphoma
m-BACOD regimen Non-Hodgkin's lymphoma
MACOP-B regimen Non-Hodgkin's lymphoma
MCOP regimen Non-Hodgkin's lymphoma
MINE regimen Non-Hodgkin's lymphoma, Hodgkin's lymphoma
MINE-R regimen Non-Hodgkin's lymphoma, Hodgkin's lymphoma
Mini-BEAM regimen Hodgkin's lymphoma
Mito-FLAG regimen Acute myelogenous leukemia
MOPP regimen Hodgkin's lymphoma
MVAC regimen Bladder cancer
PCV regimen Oligodendroglial tumors
POG 9245 regimen Hodgkin's lymphoma
ProMACE-CytaBOM regimen Non-Hodgkin's lymphoma
ProMACE-MOPP regimen Diffuse large B-cell lymphoma, primary CNS lymphoma
R-CDOP regimen Non-Hodgkin's lymphoma
R-CEOP regimen Diffuse large B-cell lymphoma
R-CHMP regimen Non-Hodgkin's lymphoma
R-CHOEP-14 regimen Diffuse large B-cell lymphoma
R-CHOP regimen Diffuse large B-cell lymphoma
R-CVP regimen Diffuse large B-cell lymphoma
R-DHAOx regimen Follicular lymphoma
R-EPOCH regimen Hodgkin's lymphoma, HIV-associated lymphoma
R-ESHAP regimen Diffuse large B-cell lymphoma
R-FCM regimen Chronic lymphocytic leukemia
R-FMC regimen Chronic lymphocytic leukemia
R-GCVP regimen Diffuse large B-cell lymphoma
R-HCVAD regimen Mantle cell lymphoma
R-MA regimen Mantle cell lymphoma
R-MINE regimen Hodgkin's lymphoma, non-Hodgkin's lymphoma
R2CHOP regimen Diffuse large B-cell lymphoma
RCD regimen Non-hodgkin lymphoma, CLL
RdC regimen AL amyloidosis
RVD regimen Multiple myeloma
SMILE regimen NK/T cell lymphoma
Stanford V regimen Hodgkin's lymphoma
TAC regimen Breast cancer
TAP regimen Endometrial cancer
TC regimen Breast cancer
TCH regimen Breast cancer
Thal/Dex regimen Multiple myeloma
TIP regimen Head and neck cancer, Testicular cancer
VAC regimen Small cell lung cancer
VAD regimen Multiple myeloma
VAPEC-B regimen Non-Hodgkin lymphoma
VCAP-AMP-VECP regimen Human T-lymphotropic virus type I-associated Adult T-cell leukemia-lymphoma
VeIP regimen Germ cell tumor
VIP regimen Germ cell tumor, Thymoma
VR-CHOP regimen Diffuse large B-cell lymphoma and Mantle cell lymphoma
VTD-PACE regimen Multiple myeloma

External Links

Retrieved from "https://www.wikidoc.org/index.php?title=List_of_chemotherapy_regimens&oldid=1082696"